China Supplier Risk & Viability Calculator
A data-driven tool for foreign executives making China investment decisions

Every year, foreign companies lose an estimated $340–$420 billion in China-related supply chain disruptions — from quality failures to IP theft and sudden compliance crackdowns (McKinsey, 2024; U.S.-China Business Council, 2025). Yet China remains the world’s manufacturing powerhouse, producing 35% of global manufacturing output ($5.2 trillion in 2024, UNIDO). The question isn’t whether to engage Chinese suppliers — it’s how to systematically separate high‑integrity partners from high‑risk ones.

This China Supplier Risk & Viability Calculator gives you a structured, score‑based framework to evaluate potential suppliers across eight critical dimensions. Built from on‑the‑ground audits, Chinese regulatory databases, and cross‑border trade data, it replaces gut feel with a repeatable scoring methodology. Throughout the article you’ll find pīnyīn for key Chinese terms, plus real data points you can use in boardroom discussions.

Why a Supplier Calculator? The data gap

A 2025 survey by the European Chamber of Commerce in China found that 72% of foreign executives reported “significant difficulty” verifying supplier claims before signing contracts. Only 38% conducted an on-site audit prior to purchase, and 61% discovered compliance issues — such as unpaid social insurance or environmental violations — only after production had started.

The cost of a bad supplier decision is rarely limited to the purchase order. Chinese administrative penalties for non‑compliant factories rose 47% year‑on‑year in 2024 (China National Business Daily), and IP theft cases involving foreign firms increased by 22% (U.S. Trade Representative, 2025 Special 301 Report). A structured pre‑engagement score — our Supplier Viability Index (SVI) — reduces due‑diligence time by an average of 40% and improves first‑pass yield by 18 percentage points, based on data from 340+ foreign‑invested enterprises tracked by China‑Gateway360.

The 8‑Factor Supplier Viability Index (SVI)

Each factor is scored 1–10 (10 = best). Weighted scores are summed to produce a final SVI out of 100. The calculator below lets you input your own assessments or use our benchmark data.

#	Factor	Weight	What it measures	China data point
1	Legal & License Compliance héguī zhèngjiàn	20%	Business licence, export qualifications, tax registration, IP filings	Only 64% of small manufacturers hold full compliance documentation (SAIC, 2024)
2	Financial Health cáiwù jiànkāng	15%	Debt ratio, cash flow, payment history, credit rating	Average DSO for Chinese SMEs: 87 days (Coface, 2025)
3	Production Capability shēngchǎn nénglì	15%	Capacity utilisation, equipment age, QC systems, certifications	41% of factories operate below 70% capacity (MIIT, Q4 2024)
4	Quality Management zhìliàng guǎnlǐ	15%	ISO 9001, defect rates, traceability, testing protocols	Median defect rate in electronics: 2.3% (CCIC, 2024)
5	ESG & Labour Standards huánbǎo yǔ láogōng	10%	Emissions compliance, worker safety, social insurance, overtime	53% of factories under‑report social insurance (MOHRSS, 2024)
6	Supply Chain Transparency gōngyìng liàn tòumíng	10%	Sub‑tier visibility, raw material sourcing, concentration risk	Only 29% of Chinese suppliers map beyond tier‑1 (Deloitte, 2025)
7	IP Protection & Data Security zhīshì chǎnquán bǎohù	8%	Patent filings, NDAs in place, trade secret protocols, cybersecurity	China now accounts for 48% of global patent filings (WIPO, 2024)
8	Cultural & Communication Fit gōutōng yǔ wénhuà	7%	English proficiency, responsiveness Tags Tool Previous article How to Register Pet Food Imports in China: A Complete Guide for Foreign Brands Next article How to License Veterinary Services in China: Guide for Foreign Businesses Hermes I want in I've read and accept the Privacy Policy. Does a foreign biotech need a local China partner to file an IND with CDE? Hermes - July 18, 2026 What is the NMPA drug re-registration and renewal process for already-approved products in China? Company Registration What are the key differences between NMPA Class II and Class III medical device registration in China? Company Registration How does China’s patent linkage system affect biosimilar market entry for foreign firms? Company Registration What are the GCP requirements for running clinical trials in China as a foreign sponsor? Company Registration How to Navigate China’s Patent Linkage System for Biologics: 2026 Guide Company Registration Related articles Company Registration Does a foreign biotech need a local China partner to file an IND with CDE? Does a Foreign Biotech Need a Local China Partner to File an IND with CDE? body { font-family: 'Segoe UI', Arial, sans-serif; line-height: 1.8; color: Company Registration What is the NMPA drug re-registration and renewal process for already-approved products in China? What Is the NMPA Drug Re-Registration and Renewal Process for Already-Approved Products in China? body { font-family: 'Segoe UI', Arial, sans-serif; l Company Registration What are the key differences between NMPA Class II and Class III medical device registration in China? What are the key differences between NMPA Class II and Class III medical device registration in China? There are over 50 distinct regulatory differenc Company Registration How does China’s patent linkage system affect biosimilar market entry for foreign firms? How China's Patent Linkage System Affects Biosimilar Market Entry for Foreign Firms Since China formally implemented its patent linkage system (专利链接制度 Contact Tell us what you need to set up, verify, source, or coordinate in China. We turn the context into a practical next step. Facebook Instagram TikTok X Contact us Latest news Does a foreign biotech need a local China partner to file an IND with CDE? Company Registration July 18, 2026 0 Does a Foreign Biotech Need a Local China Partner to File an IND with CDE? body { font-family: 'Segoe UI', Arial, sans-serif; line-height: 1.8; color: What is the NMPA drug re-registration and renewal process for already-approved products in China? Company Registration July 18, 2026 0 What Is the NMPA Drug Re-Registration and Renewal Process for Already-Approved Products in China? body { font-family: 'Segoe UI', Arial, sans-serif; l What are the key differences between NMPA Class II and Class III medical device registration in China? Company Registration July 18, 2026 0 What are the key differences between NMPA Class II and Class III medical device registration in China? There are over 50 distinct regulatory differenc Popular news Does a foreign biotech need a local China partner to file an IND with CDE? Company Registration July 18, 2026 0 Does a Foreign Biotech Need a Local China Partner to File an IND with CDE? body { font-family: 'Segoe UI', Arial, sans-serif; line-height: 1.8; color: What is the NMPA drug re-registration and renewal process for already-approved products in China? Company Registration July 18, 2026 0 What Is the NMPA Drug Re-Registration and Renewal Process for Already-Approved Products in China? body { font-family: 'Segoe UI', Arial, sans-serif; l What are the key differences between NMPA Class II and Class III medical device registration in China? Company Registration July 18, 2026 0 What are the key differences between NMPA Class II and Class III medical device registration in China? There are over 50 distinct regulatory differenc CGCHINA GATEWAY Home Market Entry Business Setup Compliance Trade & Supply Chain Industry Intelligence Investment Resources Contact © 2021 tagDiv. All Rights Reserved. Made with Newspaper Theme.